Product Name:3-Amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one
IUPAC Name:3-amino-2-(3-methoxyphenyl)-3,4-dihydroquinazolin-4-one
| Packing Unit | Available Stock | Price($) | Quantity |
|---|---|---|---|
| CM214189-1g | 1-2 Weeks | ǪŌŮ |
|
|
|||
| Product Overview |
3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one, also known as PD153035, is a small molecule inhibitor that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. |
| Synthesis Method |
3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one can be synthesized through a multistep process starting from commercially available 3-methoxyaniline. The first step involves the reaction of 3-methoxyaniline with 2-chloroacetyl chloride in the presence of a base to yield 2-(3-methoxyphenyl)-N-(2-chloroacetyl)aniline. This intermediate is then reacted with 2-aminobenzoic acid in the presence of a dehydrating agent to form 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one. |
| Chemical Properties |
It is a synthetic compound that may have off-target effects or toxicity, which could affect the interpretation of experimental results. 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one is not a selective inhibitor and may also inhibit other kinases that share structural similarities with EGFR. |
| Synthesis and Application |
It has been shown to inhibit the growth and proliferation of various cancer cell lines in vitro and in vivo, including lung, breast, and colon cancer. 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one works by binding to the ATP-binding site of EGFR and preventing its activation, thereby inhibiting downstream signaling pathways that promote cell growth and survival. In addition to cancer treatment, 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one has also been investigated for its potential use in treating other diseases, such as Alzheimer's disease and Parkinson's disease, due to its ability to cross the blood-brain barrier and inhibit EGFR activity in the brain. |
| Future Directions |
One area of research is the development of more selective and potent inhibitors of EGFR that can overcome the limitations of 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one. Another area of research is the investigation of the role of EGFR in other diseases, such as neurodegenerative diseases and autoimmune diseases. Additionally, the use of 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one in combination with other therapeutic agents, such as chemotherapy or immunotherapy, is an area of research that has the potential to improve cancer treatment outcomes. Finally, the use of 3-amino-2-(3-methoxyphenyl)quinazolin-4(3H)-one as a tool for studying the role of EGFR in various biological processes, such as cell differentiation and migration, is an area of research that has the potential to advance our understanding of this important signaling pathway. |
Search 
+86 21 5895 0110 
